fda glp-1 warning letters october 2025 news issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading FDA Issues Warning Letters to

Other non-entero-pancreatic hormone-based pharmacotherapies such as bimagrumab and growth differentiation factor 15 (GDF-15) are also under investigation

Rowland on the Eastern Division is presiding over these cases, where discovery is currently ongoing

Incretin-based therapies have been associated with a body weight (BW) reduction of 5% in at least half of patients in most randomized controlled trials (RCT) and real-world studies (RWS)

This specialized design ensures that users receive the exact amount of insulin prescribed by their healthcare provider

4 Epidermal Growth Factor (EGF) (5,000 mg) Promotes cell regeneration, helping to repair and rejuvenate damaged skin